Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection

NACompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 1996

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

Isoniazid

DRUG

Pyridoxine hydrochloride

Trial Locations (14)

10011

Clinical Directors Network of Region II, New York

10037

Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York

10456

Bronx Lebanon Hosp Ctr, The Bronx

11201

Addiction Research and Treatment Corp, Brooklyn

19899

Wilmington Hosp / Med Ctr of Delaware, Wilmington

20422

Veterans Administration Med Ctr / Regional AIDS Program, Washington D.C.

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Comprehensive AIDS Alliance of Detroit, Detroit

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

80204

Denver CPCRA / Denver Public Hlth, Denver

90095

UCLA Med Ctr, Los Angeles

94110

Community Consortium of San Francisco, San Francisco

06519

Hill Health Corp, New Haven

07103

North Jersey Community Research Initiative, Newark

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000959 - Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection | Biotech Hunter | Biotech Hunter